Literature DB >> 29110758

APOL1 Renal Risk Variants: Fertile Soil for HIV-Associated Nephropathy.

Jeffrey B Kopp1, Jurgen Heymann2, Cheryl A Winkler3.   

Abstract

Apolipoprotein L1 (APOL1) genetic variants are potent risk factors for glomerular disease, but one or more additional factors are required for expression of glomerular disease. Uncontrolled or poorly controlled human immunodeficiency virus (HIV) infection is the most potent susceptibility factor for APOL1 nephropathy that has been identified to date. APOL1 variants are associated with HIV-associated nephropathy (HIVAN), a podocyte disease, but not with HIV-immune complex disease, primarily a disease of the mesangium. The mechanism by which HIV brings out the latent glomerular disease risk remains to be defined. There are at least two classes of candidate mechanisms to explain the potent interaction between HIV-1 and APOL1. First, APOL1 variant proteins and HIV accessory proteins implicated in HIVAN may target the same or related intracellular pathways in podocytes. Recent data suggest roles for interleukin 1b and transcription factor EB. Second, features of uncontrolled HIV infection, including increased circulating factors such as interferon, may drive APOL1 gene transcription or act upon podocytes in other ways. Deeper probing of APOL1-HIV interactions may yield insights that will aid in understanding HIVAN, APOL1 nephropathy, and podocyte biology. Published by Elsevier Inc.

Entities:  

Keywords:  Chronic kidney disease; Nef; Vpr; interferon

Mesh:

Substances:

Year:  2017        PMID: 29110758      PMCID: PMC5745063          DOI: 10.1016/j.semnephrol.2017.07.004

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  32 in total

1.  Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease.

Authors:  Marie-Chantal Simard; Pavel Chrobak; Denis G Kay; Zaher Hanna; Serge Jothy; Paul Jolicoeur
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

3.  Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy.

Authors:  Matthew C Foy; Michelle M Estrella; Gregory M Lucas; Faryal Tahir; Derek M Fine; Richard D Moore; Mohamed G Atta
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-16       Impact factor: 8.237

4.  Brief Report: APOL1 Renal Risk Variants Are Associated With Chronic Kidney Disease in Children and Youth With Perinatal HIV Infection.

Authors:  Murli U Purswani; Kunjal Patel; Cheryl A Winkler; Stephen A Spector; Rohan Hazra; George R Seage; Lynne Mofenson; Brad Karalius; Gwendolyn B Scott; Russell B Van Dyke; Jeffrey B Kopp
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

5.  The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status.

Authors:  Michelle M Estrella; Man Li; Adrienne Tin; Alison G Abraham; Michael G Shlipak; Sudhir Penugonda; Shehnaz K Hussain; Frank J Palella; Steven M Wolinsky; Jeremy J Martinson; Rulan S Parekh; W H Linda Kao
Journal:  Clin Infect Dis       Date:  2014-10-03       Impact factor: 9.079

6.  HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics.

Authors:  Mohamed G Atta; Michelle M Estrella; Michael Kuperman; Matthew C Foy; Derek M Fine; Lorraine C Racusen; Gregory M Lucas; George W Nelson; Andrew C Warner; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-04-11       Impact factor: 10.612

7.  Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses.

Authors:  Paul J McLaren; Ali Gawanbacht; Nitisha Pyndiah; Christian Krapp; Dominik Hotter; Silvia F Kluge; Nicola Götz; Jessica Heilmann; Katharina Mack; Daniel Sauter; Danielle Thompson; Jérémie Perreaud; Antonio Rausell; Miguel Munoz; Angela Ciuffi; Frank Kirchhoff; Amalio Telenti
Journal:  Retrovirology       Date:  2015-05-16       Impact factor: 4.602

8.  Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.

Authors:  Joanna Mikulak; Ferdinando Oriolo; Federica Portale; Paolo Tentorio; Xiqian Lan; Moin A Saleem; Karl Skorecki; Pravin C Singhal; Domenico Mavilio
Journal:  Retrovirology       Date:  2016-09-06       Impact factor: 4.602

9.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Authors:  Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-07-25       Impact factor: 10.612

10.  Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1.

Authors:  Brendan Nichols; Prachi Jog; Jessica H Lee; Daniel Blackler; Michael Wilmot; Vivette D'Agati; Glen Markowitz; Jeffrey B Kopp; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  Kidney Int       Date:  2014-08-06       Impact factor: 10.612

View more
  14 in total

Review 1.  Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.

Authors:  Steve Innes; Kunjal Patel
Journal:  Curr Opin HIV AIDS       Date:  2018-05       Impact factor: 4.283

2.  Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes.

Authors:  Suzie J Scales; Nidhi Gupta; Ann M De Mazière; George Posthuma; Cecilia P Chiu; Andrew A Pierce; Kathy Hötzel; Jianhua Tao; Oded Foreman; Georgios Koukos; Francesca Oltrabella; Judith Klumperman; WeiYu Lin; Andrew S Peterson
Journal:  J Am Soc Nephrol       Date:  2020-08-06       Impact factor: 10.121

Review 3.  Apolipoprotein L1 nephropathies: 2017 in review.

Authors:  Jeffrey B Kopp; Hila Roshanravan; Koji Okamoto
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-05       Impact factor: 2.894

Review 4.  Kidney disease and APOL1.

Authors:  Aminu Abba Yusuf; Melanie A Govender; Jean-Tristan Brandenburg; Cheryl A Winkler
Journal:  Hum Mol Genet       Date:  2021-04-26       Impact factor: 6.150

5.  JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.

Authors:  Sarah E Nystrom; Guojie Li; Somenath Datta; Karen L Soldano; Daniel Silas; Astrid Weins; Gentzon Hall; David B Thomas; Opeyemi A Olabisi
Journal:  JCI Insight       Date:  2022-06-08

6.  APOL1 Risk Variants Associated with Serum Albumin in a Population-Based Cohort Study.

Authors:  Ninad S Chaudhary; Hemant K Tiwari; Bertha A Hidalgo; Nita A Limdi; Richard J Reynolds; Mary Cushman; Neil A Zakai; Leslie Lange; Suzanne E Judd; Cheryl A Winkler; Jeffrey B Kopp; Orlando M Gutiérrez; Marguerite R Irvin
Journal:  Am J Nephrol       Date:  2022-01-31       Impact factor: 4.605

7.  Impact of APOL1 Genetic Variants on HIV-1 Infection and Disease Progression.

Authors:  Ping An; Gregory D Kirk; Sophie Limou; Elizabeth Binns-Roemer; Jeffrey B Kopp; Cheryl A Winkler
Journal:  Front Immunol       Date:  2019-01-24       Impact factor: 7.561

8.  APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin.

Authors:  Sophie Uzureau; Laurence Lecordier; Pierrick Uzureau; Dorle Hennig; Jonas H Graversen; Fabrice Homblé; Pepe Ekulu Mfutu; Fanny Oliveira Arcolino; Ana Raquel Ramos; Rita M La Rovere; Tomas Luyten; Marjorie Vermeersch; Patricia Tebabi; Marc Dieu; Bart Cuypers; Stijn Deborggraeve; Marion Rabant; Christophe Legendre; Søren K Moestrup; Elena Levtchenko; Geert Bultynck; Christophe Erneux; David Pérez-Morga; Etienne Pays
Journal:  Cell Rep       Date:  2020-03-17       Impact factor: 9.423

9.  APOL1 polymorphism modulates sphingolipid profile of human podocytes.

Authors:  Manuela Valsecchi; Valentina Cazzetta; Ferdinando Oriolo; Xiqian Lan; Rocco Piazza; Moin A Saleem; Pravin C Singhal; Domenico Mavilio; Joanna Mikulak; Massimo Aureli
Journal:  Glycoconj J       Date:  2020-09-11       Impact factor: 2.916

Review 10.  The function of apolipoproteins L (APOLs): relevance for kidney disease, neurotransmission disorders, cancer and viral infection.

Authors:  Etienne Pays
Journal:  FEBS J       Date:  2020-06-25       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.